These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

598 related items for PubMed ID: 11394505

  • 21. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
    Lopes de Menezes DE, Denis-Mize K, Tang Y, Ye H, Kunich JC, Garrett EN, Peng J, Cousens LS, Gelb AB, Heise C, Wilson SE, Jallal B, Aukerman SL.
    J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
    [Abstract] [Full Text] [Related]

  • 22. Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists.
    Bremer E, ten Cate B, Samplonius DF, Mueller N, Wajant H, Stel AJ, Chamuleau M, van de Loosdrecht AA, Stieglmaier J, Fey GH, Helfrich W.
    Cancer Res; 2008 Jan 15; 68(2):597-604. PubMed ID: 18199557
    [Abstract] [Full Text] [Related]

  • 23. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A, Hasenkamp J, Engelke M, Burkhart N, Trümper L, Wienands J, Glass B.
    Exp Hematol; 2010 Mar 15; 38(3):213-21. PubMed ID: 20056126
    [Abstract] [Full Text] [Related]

  • 24. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
    Nishida M, Usuda S, Okabe M, Miyakoda H, Komatsu M, Hanaoka H, Teshigawara K, Niwa O.
    Int J Oncol; 2007 Jul 15; 31(1):29-40. PubMed ID: 17549402
    [Abstract] [Full Text] [Related]

  • 25. Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.
    Treon SP, Kelliher A, Keele B, Frankel S, Emmanouilides C, Kimby E, Schlossman R, Mitsiades N, Mitsiades C, Preffer F, Anderson KC.
    Semin Oncol; 2003 Apr 15; 30(2):248-52. PubMed ID: 12720146
    [Abstract] [Full Text] [Related]

  • 26. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.
    Gorter A, Blok VT, Haasnoot WH, Ensink NG, Daha MR, Fleuren GJ.
    Lab Invest; 1996 Jun 15; 74(6):1039-49. PubMed ID: 8667608
    [Abstract] [Full Text] [Related]

  • 27. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
    Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B.
    Cancer Res; 2005 Jan 01; 65(1):264-76. PubMed ID: 15665303
    [Abstract] [Full Text] [Related]

  • 28. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
    Shi YX, Zhang XS, Xia JC, Li YQ, Xu RH, Han WJ, Zhang JH, Guan ZZ, Jiang WQ.
    Ai Zheng; 2007 Aug 01; 26(8):837-42. PubMed ID: 17697543
    [Abstract] [Full Text] [Related]

  • 29. Immunotherapeutic strategies for the treatment of plasma cell malignancies.
    Treon SP, Raje N, Anderson KC.
    Semin Oncol; 2000 Oct 01; 27(5):598-613. PubMed ID: 11049026
    [Abstract] [Full Text] [Related]

  • 30. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
    Behr TM, Wörmann B, Gramatzki M, Riggert J, Gratz S, Béhé M, Griesinger F, Sharkey RM, Kolb HJ, Hiddemann W, Goldenberg DM, Becker W.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
    [Abstract] [Full Text] [Related]

  • 31. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.
    van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB.
    Clin Cancer Res; 2006 Jul 01; 12(13):4027-35. PubMed ID: 16818702
    [Abstract] [Full Text] [Related]

  • 32. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
    Bonavida B, Vega MI.
    Drug Resist Updat; 2005 Jul 01; 8(1-2):27-41. PubMed ID: 15939340
    [Abstract] [Full Text] [Related]

  • 33. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
    Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A, Introna M.
    Blood; 2000 Jun 15; 95(12):3900-8. PubMed ID: 10845926
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.
    Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC, Byrd JC.
    J Clin Oncol; 2003 Apr 15; 21(8):1466-71. PubMed ID: 12697868
    [Abstract] [Full Text] [Related]

  • 36. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
    Davis TA, Czerwinski DK, Levy R.
    Clin Cancer Res; 1999 Mar 15; 5(3):611-5. PubMed ID: 10100713
    [Abstract] [Full Text] [Related]

  • 37. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ, Yamada RE, Kafi K, Said J, van Rooijen N, Timmerman JM.
    J Immunother; 2009 Mar 15; 32(6):622-31. PubMed ID: 19483647
    [Abstract] [Full Text] [Related]

  • 38. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
    Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS.
    Clin Cancer Res; 2008 Mar 01; 14(5):1550-60. PubMed ID: 18316580
    [Abstract] [Full Text] [Related]

  • 39. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells.
    Hayden-Ledbetter MS, Cerveny CG, Espling E, Brady WA, Grosmaire LS, Tan P, Bader R, Slater S, Nilsson CA, Barone DS, Simon A, Bradley C, Thompson PA, Wahl AF, Ledbetter JA.
    Clin Cancer Res; 2009 Apr 15; 15(8):2739-46. PubMed ID: 19351771
    [Abstract] [Full Text] [Related]

  • 40. Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets.
    Maloney DG.
    Semin Oncol; 2005 Feb 15; 32(1 Suppl 1):S19-26. PubMed ID: 15786022
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.